Search results
Showing 46 to 59 of 59 results for botulinum a toxin
reported. Source guidance details Comes from guidance Botulinum toxin type A injections into the urethral sphincter for...
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
This quality standard covers managing urinary incontinence in women (aged 18 and over). It covers assessment, care and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS77Show all sections
Sections for QS77
- Quality statements
- Quality statement 1: Initial assessment
- Quality statement 2: Bladder diaries and lifestyle changes
- Quality statement 3: Containment products
- Quality statement 4: Supervised pelvic floor muscle training
- Quality statement 5: Bladder training
- Quality statement 6: Indwelling catheters
- Quality statement 7: Multidisciplinary team review before surgery or invasive treatment
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.
Idiopathic overactive bladder syndrome: botulinum toxin A (ESNM2)
This evidence summary has been replaced by NICE guideline CG171.
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (IPG487)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.
CG145/3 | Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum...
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Transcutaneous microwave ablation for severe primary axillary hyperhidrosis (IPG601)
Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis in adults. This involves using microwaves to destroy sweat glands in the armpit.